WO/2015/152761 DEVICE FOR ELECTROLYTIC PRODUCTION OF A GASEOUS MIXTURE OF HYDROGEN AND OXYGEN||WO||08.10.2015|
||PCT/RU2014/000274||KUZNETSOV, Alexandr Urievich||KUZNETSOV, Alexandr Urievich|
This invention relates to the field of electrochemistry. The present device for the electrolytic production of a gaseous mixture of hydrogen and oxygen contains an electrolyser which comprises a housing containing electrodes in the form of plates, said electrodes being electrically connected to a power supply. The electrodes are configured in the form of a set of spaced apart stainless steel plates with vertical and horizontal saw cuts in the surfaces thereof and with openings for the circulation of electrolyte and the removal of gases, said openings being provided in each plate so as to be non-coaxial with the openings in the adjacent plates. The electrolyte is a weak solution of water and sodium hydroxide. An electrolyte receptacle is configured as a closed and sealed receptacle with an inlet for filling the space inside the receptacle with electrolyte so that an empty space is formed above the surface of the electrolyte; the receptacle is connected to a channel for removing a mixture of gas and water from the electrolyser, and a channel for collecting a gaseous mixture of hydrogen and oxygen, which has a water lock mounted therein, is connected to the empty space of the electrolyte receptacle. At the same time, the electrolyser housing contains at least one source for emitting ultrasonic radiation into the water-based electrolyte in order to weaken the molecular bonds of said electrolyte; the housing also contains a source of ultraviolet radiation for acting on the electrolyte.
WO/2015/057659 SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS||WO||23.04.2015|
||PCT/US2014/060418||EISAI R&D MANAGEMENT CO., LTD.||CARLSON, Eric|
Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.
WO/2015/049053 NON-SLIP TREAD WITH ALVEOLAR STRUCTURE||WO||09.04.2015|
||PCT/EP2014/002675||AL.PI. S.R.L.||BIANCUCCI, Demetrio|
The present invention concerns a non-slip tread, applicable to the footwear sector, having in correspondence of the heel and the front half-sole, two areas with alveolar structure whose cells consist of walls (2) converging on a hole (3) to form a funnel-shaped surface. Each hole (3) is a through hole, that is, it passes right through the thickness of the tread (1) and communicates with a transverse channel (4) for lateral outflow made inside the tread (1).
WO/2015/048363 SUBSTITUTED QUINOLIZINE DERIVATIVES USEFUL AS HIV INTEGRASE INHIBITORS||WO||02.04.2015|
||PCT/US2014/057572||MERCK SHARP & DOHME CORP.||YU, Tao|
The present invention relates to Substituted Quinolizine Derivatives of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein X, Y, R1, R2, R3, R4, R5, R9 and R10 are as defined herein. The present invention also relates to compositions comprising at least one Substituted Quinolizine Derivative, and methods of using the Substituted Quinolizine Derivatives for treating or preventing HIV infection in a subject.
WO/2015/041624 ENVELOPE FOR PACKING OF SMALL PIECE GOODS AND FLEXIBLE WRAPPING MATERIAL FOR MANUFACTURE OF IT||WO||26.03.2015|
||PCT/UA2013/000132||MIROCHNIK, Irina||MIROCHNIK, Irina|
Envelope (1) for small goods comprised of contact areas of at least single-layer inner and outer laminate structures, in which parts projecting beyond ends of a column of packed goods are shaped as tightly closed butt-end caps (2). A reed flap (3), which is suitable for repeated opening and closing and in which a line of perforation (5) confines the reed (4) is located nearby at least one of said butt-end caps. A flexible wraping material for the envelope is shaped as a long-length band that is comprised of many prospective uniform envelopes' blank-segments. Each blank-segment has contact areas of at least single-layer inner and outer laminate structures and a zone meant for formation of a prospective reed flap (4) confined by a line of perforation (5). Each line of perforation is made only in the outer laminate structure, and each prospective reed is placed initially onto the inner laminate structure. This decreases substantially the probability of accidental ruptures of filled envelopes.
WO/2015/036134 LADLE BOTTOM AND LADLE||WO||19.03.2015|
||PCT/EP2014/063565||REFRACTORY INTELLECTUAL PROPERTY GMBH & CO. KG||KÖHLER, Sarah|
The invention relates to a ladle bottom being part of a metallurgical ladle for treating a metal melt as well as a corresponding metallurgical ladle.
WO/2015/036369 METHOD TO TREAT ONYCHOMYCOSIS BY HYDROXYPROPYL CHITOSAN||WO||19.03.2015|
||PCT/EP2014/069099||POLICHEM S.A.||MAILLAND, Federico|
The present invention is directed to a method to treat onychomycosis by topically administering a composition which contains hydroxypropyl chitosan as the sole active ingredient and, in particular, by administering a nail topical composition consisting essentially of: a) hydroxypropyl chitosan, b) water, c) at least a lower alkanol.
WO/2015/036370 PIDOTIMOD FOR USE IN THE TREATMENT OF INFLAMMATION-ASSOCIATED DISEASES||WO||19.03.2015|
||PCT/EP2014/069103||POLICHEM S.A.||CARUSO, Arnaldo|
The present invention relates to a novel use of the active ingredient Pidotimod, or its stereoisomers and/or physiologically acceptable salts thereof, to treat inflammation-associated diseases characterized by an aberrant hyperactivation of the non canonical NFkB pathway, such as allergic diseases, autoimmune diseases or other inflammatory diseases based on mechanisms different from allergic or autoimmune.
WO/2015/038503 HETEROCYCLE-SUBSTITUTED BICYCLIC AZOLE PESTICIDES||WO||19.03.2015|
||PCT/US2014/054671||E. I. DU PONT DE NEMOURS AND COMPANY||CLARK, David, Alan|
Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, and A, R1, m, X1, X2, X3, X4, Y1, Y2 and Y3 are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound or a composition of the invention.
WO/2015/027163 IMMUNO-ONCOLYTIC THERAPIES||WO||26.02.2015|
||PCT/US2014/052308||UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION||THORNE, Stephen, Howard|
The present invention relates to oncolytic vaccinia viruses which have been modified to promote anti-tumor immunity and/or reduce host immunity and/or antibody response against the virus. It is based, at least in part, on the discovery that oncolytic vaccinia virus (i) bearing a genome deletion of a gene that reduces T cell immunity (interleukin-18 binding protein); (ii) treated with a sialidase enzyme which is believed to reduce TLR2 activation and therefore the antibody response; (iii) carrying a gene that enhances cytotoxic T lymphocyte induction (e.g., TRIF) and/or (iv) reduces tumor myeloid-derived suppressor cells by reducing prostaglandin E2 reduces tumor growth. Accordingly, the present invention provides for immunooncolytic vaccinia viruses and methods of using them in the treatment of cancers.